Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Milestone Asset Management LLC

Milestone Asset Management LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 170.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 60,343 shares of the biopharmaceutical company's stock after purchasing an additional 38,066 shares during the quarter. Gilead Sciences comprises approximately 1.4% of Milestone Asset Management LLC's investment portfolio, making the stock its 12th biggest holding. Milestone Asset Management LLC's holdings in Gilead Sciences were worth $6,761,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Redwood Financial Network Corp raised its position in shares of Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after acquiring an additional 98 shares during the period. Nicolet Advisory Services LLC lifted its holdings in Gilead Sciences by 2.9% during the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares in the last quarter. CFO4Life Group LLC lifted its holdings in Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock worth $394,000 after buying an additional 112 shares in the last quarter. Howe & Rusling Inc. lifted its holdings in Gilead Sciences by 2.5% during the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after buying an additional 115 shares in the last quarter. Finally, Atalanta Sosnoff Capital LLC lifted its holdings in Gilead Sciences by 4.7% during the 4th quarter. Atalanta Sosnoff Capital LLC now owns 2,648 shares of the biopharmaceutical company's stock worth $245,000 after buying an additional 119 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 1.8%

Gilead Sciences stock traded up $1.95 during trading hours on Thursday, reaching $110.97. The company had a trading volume of 4,627,772 shares, compared to its average volume of 7,723,252. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96. The firm has a market cap of $138.04 billion, a price-to-earnings ratio of 299.92, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a 50-day moving average price of $105.40 and a 200 day moving average price of $101.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the company earned ($1.32) EPS. The company's revenue for the quarter was down .3% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Finally, Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $110.55.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,929 shares of company stock valued at $6,748,980 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.